EmactuzumabEmactuzumab
MedChemExpress (MCE)
HY-P99245
1448221-67-7
RG 7155
RO 5509554
97.60%
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping with dry ice.
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (Kd = 0.2 nM) to blocks CSF-1R dimerization[2]. RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM by inducing cell death[2]. RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages[2].
Emactuzumab(RG 7155) (i.v.
0.1、1、10、30 and 100 mg/kg
once) increases CSF-1 concentration in nonhuman primates’ peripheral blood[2]. RG7155 (i.v.
0, 30, and 100 mg/kg
once weekly
for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo[2].
IC50: 0.2 nM (CSF-1R)[2] In Vitro Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (Kd = 0.2 nM) to blocks CSF-1R dimerization[2]. RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM by inducing cell death[2]. RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Emactuzumab Related Antibodies Cell Viability Assay[2] Cell Line: CSF-1 and/or GM-CSF Macrophages
Humanized
Human IgG1 kappa
Human IgG1 kappa, Isotype Control
| | | |
| | | | | |
[1]. Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug
16(8):949-56. [Content Brief]
[2]. Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16
25(6):846-59. [Content Brief]